AstraZeneca is unveiling a wealth of data at the European Society for Medical Oncology (ESMO) Congress from October 20 to 24, 2023, to further its mission to eradicate cancer as a leading cause of death. Their portfolio and pipeline will be showcased in nearly 100 abstracts, which encompass 19 approved and potential new medications. The conference includes two highly anticipated Presidential Symposia:
- TROPION-Lung01: This Phase III trial evaluates datopotamab deruxtecan (Dato-DXd), developed by AstraZeneca and Daiichi Sankyo, in previously treated advanced non-small cell lung cancer (NSCLC). The trial results are being presented in a Presidential Symposium on Monday, October 23.
- TROPION-Breast01: This Phase III trial explores datopotamab deruxtecan in patients with previously treated inoperable or metastatic hormone receptor (HR)-positive, HER2-low, or negative breast cancer. It will be featured in a Presidential Symposium on Monday, October 23.
Other important findings to be presented at ESMO include:
- FLAURA2: Data from this Phase III trial of Tagrisso (osimertinib) plus chemotherapy in EGFR-mutated (EGFRm) advanced NSCLC, highlighting safety and central nervous system metastases outcomes.
- DUO-E: Results from this Phase III trial of Imfinzi (durvalumab) combined with platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) as maintenance therapy in newly diagnosed advanced or recurrent endometrial cancer.
- MATTERHORN: Data from the Phase III trial of Imfinzi plus neoadjuvant chemotherapy for patients with resectable, early-stage, and locally advanced gastric and gastroesophageal junction cancers.
- DESTINY-PanTumor02: This Phase II trial, investigates Enhertu (trastuzumab deruxtecan) in previously treated HER2-expressing advanced solid tumors. The data includes progression-free survival (PFS) and overall survival (OS) results from the primary analysis.
Furthermore, multiple presentations will delve into AstraZeneca’s clinical program of novel immuno-oncology (IO) bispecific antibodies, including the advanced clear cell renal cell carcinoma treatment volrustomig (MEDI5752), which targets PD-1/CTLA-4. Additional data on rilvegostomig (AZD2936, targeting PD-1/TIGIT) and sabestomig (AZD7789, targeting PD-1/TIM3) in lung cancer will also be provided.
These findings, spanning various cancer types, underscore AstraZeneca’s dedication to redefining cancer care and offering new treatment options for patients with high unmet needs. The data will emphasize the strength of novel medication combinations and the potential for personalized therapies.
In the battle against cancer, AstraZeneca’s continued scientific innovation and data-driven approach contribute to its vision of eliminating cancer as a leading cause of death.
For additional information and detailed results, the upcoming ESMO Congress from October 20 to 24, 2023, is an essential event for oncologists, healthcare professionals, and the broader medical community. It will provide a comprehensive understanding of the latest advancements in cancer treatment. AstraZeneca’s extensive data presentation demonstrates their commitment to providing innovative cancer therapies across multiple cancer types, helping to improve patient outcomes.
It’s important to note that this information is based on preliminary data shared by AstraZeneca ahead of the ESMO Congress, and the full details will be presented at the event. Healthcare professionals and researchers attending the ESMO Congress will have the opportunity to engage with these findings and explore their implications for cancer treatment.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
